PeproMene Bio Secures $11 Million Investment for Innovative CAR-T Therapy Advancement
PeproMene Bio Secures $11 Million Investment for Innovative CAR-T Therapy Advancement
On December 19, 2024, PeproMene Bio, Inc. announced a significant investment of $11 million from the Institute for Follicular Lymphoma Innovation (IFLI). This funding aims to facilitate the development of PMB-CT01, an innovative CAR T cell therapy specifically designed for patients with relapsed/refractory follicular lymphoma.
The investment comprises an advance of $6 million, followed by $5 million in conditional funding from IFLI. This collaboration reflects the promising outcomes reported in the Phase 1 study PMB-102, which has shown potential in treating patients with B-NHL (B-cell Non-Hodgkin Lymphoma).
The Phase 1 expansion of the PMB-102 study will now include patients suffering from recurrent or refractory follicular lymphoma, allowing for a deeper evaluation of the safety and efficacy of PMB-CT01 in this demographic that has undergone extensive prior treatments.
PMB-CT01 has been developed by City of Hope, a leading cancer research and treatment organization, as a viable alternative for the many patients who relapse after standard treatments, including CD19 CAR T cell therapy. The Phase 1 trial results are encouraging, with a 100 percent response rate observed in the initial six patients treated with PMB-CT01, showing only mild treatment adverse effects.
Dr. Hazel Cheng, Chief Operating Officer at PeproMene Bio, emphasized the urgent need for effective treatments post-CD19 CAR T therapy, stating, "We are deeply committed to the scientific and clinical development of this potentially promising cell therapy for relapsed/refractory follicular lymphoma and other B-cell malignancies."
Dr. Elizabeth Budde, the principal investigator of the trial, highlighted the significance of these early results, noting that most of the initial trial participants had previously relapsed after receiving CD19 CAR T therapy or exhibited CD19-negative tumors. This underscores PMB-CT01's potential as a compelling therapeutic option for patients facing limited alternatives.
The innovative characteristics of the BAFF-R CAR T therapy lie in its unique targeting mechanism. The BAFF receptor (BAFF-R), predominantly expressed on B cells, is pivotal for their growth and survival. As such, it is unlikely that tumor cells would evade this treatment by losing the BAFF-R antigen, making the therapy an exciting possibility for managing B-cell malignancies.
PeproMene Bio's commitment to advancing PMB-CT01 is significant, especially for the relapsed/refractory follicular lymphoma population, bringing hope for more effective treatment outcomes. Dr. Michel Azoulay, medical director of IFLI, expressed enthusiasm over the potential benefits of the therapy, stating, "PMB-CT01 has a tremendous potential in improving outcomes for patients with non-Hodgkin lymphomas, particularly follicular lymphoma."
For more detailed information about PeproMene Bio’s ongoing projects and this significant therapeutic advance, visit their official website at pepromenebio.com and for insights about IFLI, check i-fli.org.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.